Odimma is a biotech company that focuses on precision medicine and cure for personalized cancer immunotherapy.
Odimma has raised $2.0M in total funding. The most recent round was Seed. The last funding was announced in April 2023.
Odimma's investors include Bpifrance, Alsace Business Angels, Capital Grand Est, Angels Santé.
Odimma is headquartered in Illkirch-graffenstaden, France.
Odimma is a biotech company that focuses on precision medicine and cure for personalized cancer immunotherapy.
Odimma is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Odimma — Funding & Investors." VCBacked, April 13, 2023, https://www.vcbacked.co/company/odimma. Accessed September 30, 2026.
VCBacked. (2023). Odimma — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/odimma
{{cite web |title=Odimma — Funding & Investors |url=https://www.vcbacked.co/company/odimma |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated